Popular
BlogNEW
CompaniesNEW
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Phesgo and Tecentriq Performance and Approvals slide image

Phesgo and Tecentriq Performance and Approvals

Major granted approvals 2023 US Polivy Xofluza EU RG7596 1L DLBCL (US) April 2023 RG6152 influenza pediatric RG7596 Jan 2023 Hemlibra RG6013 moderate hemophilia A Jan 2023 RG7596 Status as of April 26, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases RG6152 Metabolism Neuroscience Ophthalmology Other China Polivy 1L DLBCL Jan 2023 Polivy r/r DLBCL Jan 2023 Xofluza influenza pediatric 5 to <12 years March 2023 Japan-Chugai Roche 58
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube